Compare
Arbutus Biopharma Corp vs Opus Genetics, Inc. vs Pyxis Oncology, Inc. vs CV Sciences, Inc.
| Latest fiscal year | Arbutus Biopharma Corp ABUS | Opus Genetics, Inc. IRD | Pyxis Oncology, Inc. PYXS | CV Sciences, Inc. CVSI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $14.08M | $14.20M | $13.86M | $13.79M |
| Revenue growth (YoY) | +128.2% | +29.1% | -14.2% | -12.2% |
| Gross margin | n/a | n/a | 82.8% (computed) | 49.0% |
| Operating margin | -271.0% | -271.9% | -609.2% | -3.4% |
| Net margin | -237.9% | -349.3% | -574.5% | -6.9% |
| Net income | -$33.50M | -$49.59M | -$79.62M | -$958.0K |
| EPS (Diluted) | -$0.17 | -$0.80 | -$1.28 | -$0.01 |
| Operating cash flow | -$39.64M | -$35.25M | -$63.50M | -$407.0K |
| Free cash flow | -$39.64M | n/a | -$63.51M | -$516.0K |
| Cash & equivalents | $18.01M | $45.09M | $15.42M | n/a |
| Total assets | $94.62M | $50.24M | $91.52M | $6.96M |
| Total liabilities | $18.04M | $34.90M | $38.11M | $5.49M |
| Shareholders' equity | $76.58M | $15.35M | $53.41M | $1.47M |
| Return on year-end equity | -43.7% | -323.1% | -149.1% | -65.3% |
| Shares outstanding | 192.53M | 69.89M | 62.69M | 184.26M |
Revenue, most recent five fiscal years
| Fiscal year | Arbutus Biopharma Corp | Opus Genetics, Inc. | Pyxis Oncology, Inc. | CV Sciences, Inc. |
|---|---|---|---|---|
| Latest | $14.08M Ended 2025-12-31 | $14.20M Ended 2025-12-31 | $13.86M Ended 2025-12-31 | $13.79M Ended 2025-12-31 |
| 1 year earlier | $6.17M Ended 2024-12-31 | $10.99M Ended 2024-12-31 | $16.15M Ended 2024-12-31 | $15.71M Ended 2024-12-31 |
| 2 years earlier | $18.14M Ended 2023-12-31 | $19.05M Ended 2023-12-31 | n/a | $16.00M Ended 2023-12-31 |
| 3 years earlier | $39.02M Ended 2022-12-31 | $39.85M Ended 2022-12-31 | n/a | $16.20M Ended 2022-12-31 |
| 4 years earlier | $10.99M Ended 2021-12-31 | $589.0K Ended 2021-12-31 | n/a | $20.05M Ended 2021-12-31 |